CureVac NV - ESG Rating & Company Profile powered by AI
Alternative corporations in the rating peer group for CureVac NV are displayed. The ESG score for CureVac NV indicates the company's reporting of the United Nations Sustainable Development Goals. The Disclosure rating covers 17 United Nations Sustainable Development Goals including: 'Good Health & Wellbeing', 'Responsible Production & Consumption' and 'Life below Water'.
CureVac NV in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.9; made up of an environmental score of 3.0, social score of 4.0 and governance score of 4.6.
3.9
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 1004 | Xeris Pharmaceuticals Inc | 4.0 | High |
| 1004 | Xenon Pharmaceuticals Inc | 4.0 | High |
| ... | ... | ... | |
| 1089 | CureVac NV | 3.9 | Medium |
| 1089 | Aclaris Therapeutics Inc | 3.9 | Medium |
| 1089 | Allogene Therapeutics Inc | 3.9 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does CureVac NV have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes CureVac NV disclose current and historical energy intensity?
Sign up for free to unlockDoes CureVac NV report the average age of the workforce?
Sign up for free to unlockDoes CureVac NV reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes CureVac NV disclose its ethnicity pay gap?
Sign up for free to unlockDoes CureVac NV disclose cybersecurity risks?
Sign up for free to unlockDoes CureVac NV offer flexible work?
Sign up for free to unlockDoes CureVac NV have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes CureVac NV disclose the number of employees in R&D functions?
Sign up for free to unlockDoes CureVac NV conduct supply chain audits?
Sign up for free to unlockDoes CureVac NV disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes CureVac NV conduct 360 degree staff reviews?
Sign up for free to unlockDoes CureVac NV disclose the individual responsible for D&I?
Sign up for free to unlockDoes CureVac NV disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes CureVac NV disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes CureVac NV disclose water use targets?
Sign up for free to unlockDoes CureVac NV have careers partnerships with academic institutions?
Sign up for free to unlockDid CureVac NV have a product recall in the last two years?
Sign up for free to unlockDoes CureVac NV disclose incidents of discrimination?
Sign up for free to unlockDoes CureVac NV allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas CureVac NV issued a profit warning in the past 24 months?
Sign up for free to unlockDoes CureVac NV disclose parental leave metrics?
Sign up for free to unlockDoes CureVac NV disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes CureVac NV disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes CureVac NV disclose the pay ratio of women to men?
Sign up for free to unlockDoes CureVac NV support suppliers with sustainability related research and development?
Sign up for free to unlockDoes CureVac NV disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes CureVac NV reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs CureVac NV involved in embryonic stem cell research?
Sign up for free to unlockDoes CureVac NV disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes CureVac NV disclose its waste policy?
Sign up for free to unlockDoes CureVac NV report according to TCFD requirements?
Sign up for free to unlockDoes CureVac NV disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes CureVac NV disclose energy use targets?
Sign up for free to unlockDoes CureVac NV disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes CureVac NV have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for CureVac NV
These potential risks are based on the size, segment and geographies of the company.
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.